Jan 27 (Reuters) - Biocytogen Pharmaceuticals Beijing Co Ltd 2315.HK:
FY REVENUE EXPECTED TO BE ABOUT RMB969.3 MILLION TO RMB989.3 MILLION
EXPECTED RESULT DUE TO RECOGNITION OF ANTIBODY DISCOVERY BUSINESS BY OVERSEAS CUSTOMERS, OTHERS
NET PROFIT FOR YEAR EXPECTED TO BE APPROXIMATELY RMB20 MILLION TO RMB40 MILLION
Further company coverage: 2315.HK
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.